FATE Fate Therapeutics Inc.

18.82
-0.35  -2%
Previous Close 19.17
Open 19.03
Price To Book 8.4
Market Cap 1226797396
Shares 65,185,834
Volume 438,588
Short Ratio
Av. Daily Volume 711,320

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 initial data released at SITC November 10, 2017.
FATE-NK100
Acute myelogenous leukemia (AML)
Phase 2 data due 2020.
ProTmune - PROTECT
Acute graft-versus-host disease (GvHD) undergoing hematopoietic cell transplantation (HCT)
Phase 1 trial initiated February 2018.
NK100 - DIMENSION
Solid tumors
Phase 1 dosing commenced February 2019.
FT500
Soild tumors

Latest News

  1. Edited Transcript of FATE earnings conference call or presentation 7-May-19 9:00pm GMT
  2. Fate Therapeutics, Inc. (FATE) Q1 2019 Earnings Call Transcript
  3. Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates
  4. Fate Therapeutics: 1Q Earnings Snapshot
  5. Fate Therapeutics Reports First Quarter 2019 Financial Results and Highlights Operational Progress
  6. Is Fate Therapeutics Inc (FATE) A Good Stock To Buy?
  7. Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2019 Financial Results
  8. Fate Therapeutics Announces Five Presentations at the American Society of Gene & Cell Therapy 22nd Annual Meeting
  9. Fate Therapeutics Appoints Wayne Chu, M.D. as Vice President, Clinical Development
  10. Fate Therapeutics Announces First Patient Treated with iPSC-derived NK Cell Cancer Immunotherapy FT500 Successfully Completes Initial Safety Assessment
  11. Fate Therapeutics Presents Late-Breaking Preclinical Data Highlighting Unique Advantages of Clonal Master Engineered iPSC Lines for Off-the-Shelf CAR T-cell Therapy at 2019 AACR Annual Meeting
  12. What Do Analysts Think About Fate Therapeutics, Inc.’s (NASDAQ:FATE) Earnings Trajectory?
  13. Fate Therapeutics Announces the Appointment of Karin Jooss, Ph.D. to its Board of Directors
  14. Edited Transcript of FATE earnings conference call or presentation 5-Mar-19 10:00pm GMT
  15. Fate Therapeutics Inc (FATE) Q4 2018 Earnings Conference Call Transcript
  16. Fate Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress
  17. Fate Therapeutics, Inc. to Host Earnings Call
  18. Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2018 Financial Results
  19. Cronos (CRON) to Report Q4 Earnings: What's in the Cards?
  20. Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?